Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma

JAMA Dermatol. 2021 Apr 1;157(4):468-469. doi: 10.1001/jamadermatol.2021.0058.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / adverse effects*
  • Female
  • Humans
  • Melanoma / drug therapy*
  • Melanoma / secondary
  • Necrosis
  • Nivolumab / adverse effects*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Subcutaneous Fat / pathology*

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab